Skip to content
Catalyst

PapersPMID:36904283

Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.

Nutrients2023The record ↗

  1. Finding, moderate evidenceno difference foundAll-cause mortality

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “Likewise, we did not detect any lactoferrin effects on the need for oxygen supplementation and its duration, non-invasive or mechanically assisted ventilation, or in-hospital mortality at 14 and 28 days from admission (Table 4).”
    Study
    RCT
    Duration
    4 weeks
    Dose studied
    800 mg/day bovine lactoferrin, 2 capsules of 200 mg every 12 h before meals, for 30 days
    Population
    Adults hospitalised in non-ICU wards with moderate-to-severe COVID-19 at two Italian hospitals, standard COVID-19 therapy in both arms; in-hospital mortality at 14 and 28 days

Study record

Design
randomised controlled trial
Species
human
Population
Hospitalized adult patients with moderate-to-severe COVID-19 in non-ICU COVID-19 wards at two Italian hospitals (LAC trial); oral bovine lactoferrin (Mosiac) added to standard COVID-19 therapy
Participants
218
Comparator
placebo
Duration
30 days
Endpoints measured
22